Efficacy

Choose CIMZIA when response or remission is a goal1,10

  • ​Clinical response was defined as a ≥100-point reduction in CDAI
  • Clinical remission was defined as an absolute CDAI score ≤150

Clinical response in Week 6 responders at Week 26 (ITT-NRI)1,10*†

Clinical response in Week 6 responders at Week 26 (ITT-NRI)1,10*†
Clinical response in Week 6 responders at Week 26 (ITT-NRI)1,10*†

Clinical remission in Week 6 responders at Week 26 (ITT-NRI)1,10*†

Clinical remission in Week 6 responders at Week 26 (ITT-NRI)1,10*†
Clinical remission in Week 6 responders at Week 26 (ITT-NRI)1,10*†

IMPORTANT SAFETY INFORMATION

Patients treated with CIMZIA are at an increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death. Patients greater than 65 years of age, patients with co-morbid conditions, and/or patients taking concomitant immunosuppressants (e.g., corticosteroids or methotrexate) may be at a greater risk of infection.

*Overall clinical response (decrease in CDAI ≥100 from baseline) and remission (CDAI ≤150) at Week 26 were prespecified secondary end points in PRECiSE 2.1,10

†All patients received CIMZIA 400 mg at Weeks 0, 2, and 4.1,10

CIMZIA produced clinical responses in bio-naïve and bio-experienced patients10‡

The result of this post hoc analysis should be interpreted with caution as the analysis was not prespecified in the original protocol.

  • ​​Patients with severe hypersensitivity or anaphylactic reaction and patients who were primary failures to previous anti-TNF therapy were excluded from PRECiSE 210

Among Week 6 responders10

bio-naive 69% vs. 40% circles image
bio-experienced 44% vs. 25% circles image

‡Clinical response was defined as a ≥100-point reduction in CDAI score.10
CDAI: Crohn’s Disease Activity Index; ITT-NRI: intent-to-treat non-responder imputation; Q4W: once every 4 weeks; TNF: tumor necrosis factor.

Study design

PRECiSE 21,10

  • 26-week study in patients with moderate-to-severe CD
  • All patients received CIMZIA 400 mg at 0, 2, and 4 weeks
  • Week 6 responders were randomized to CIMZIA 400 mg (n=215) or placebo (n=210) every 4 weeks
  • Overall clinical response (decrease in CDAI ≥100 from baseline) and remission (CDAI ≤150) at Week 26 were prespecified secondary end points in PRECiSE 2
  • Patients with severe hypersensitivity or anaphylactic reaction and patients who were primary failures to previous anti-TNF therapy were excluded from PRECiSE 2

Mucosal Response

CIMZIA improved CDEIS score by Week 1011

The results of the MUSIC trial should be interpreted with caution as there is a limited ability to evaluate treatment effect due to the open-label, single-arm study design that lacked a placebo control or active comparator during induction.

 

CDEIS is an instrument developed to evaluate changes in endoscopic severity based on characteristics of the ileocolonic mucosa.11

  • ​5 segments of the bowel (ileum, right colon, transverse colon, combined sigmoid and left colon, and rectum) were evaluated by presence of deep ulcerations, presence of superficial ulcerations, surface of ulcerations, surface of lesions, and presence of stenosis11
  • CDEIS scores ranged from 0-44, with higher scores indicating greater endoscopic severity11

MUSIC (open-label study): Mean CDEIS score in a subpopulation 
with endoscopic assessment at Week 10 (n=78)11

MUSIC (open-label study chart)
MUSIC (open-label study chart)

IMPORTANT SAFETY INFORMATION

Use of TNF blockers, including CIMZIA, has been associated with reactivation of hepatitis B virus in patients who are chronic carriers of the virus. In some instances, HBV reactivation occurring in conjunction with TNF-blocker therapy has been fatal.

Mucosal responses were achieved with CIMZIA

Mean (SD) CDEIS scores evaluated at Week 10 (n=78)11:

  • ​Baseline: 14.7 (5.3)
  • Week 10: 8.3 (6.0)

Subpopulation of CIMZIA patients with active CD and endoscopic assessment 
at Week 10 (n=78)11

CIMZIA assessment at Week 10 chart
CIMZIA assessment at Week 10 chart

Rates of endoscopic response, remission, and complete remission at Week 10 were secondary end points of the MUSIC study.11

Study design

MUSIC11

MUSIC was a Phase 3b, multicenter, open-label, single-arm clinical trial in 89 adult patients with moderate-to-severe ileocolonic CD. Patients had ulceration in ≥2 intestinal segments with a CDEIS score ≥8 points and active CD for ≥3 months. All patients received CIMZIA 400 mg administered at Weeks 0, 2, and 4, and then every 4 weeks until Week 52. At Week 10, patients who did not achieve a clinical response or remission increased their CIMZIA dose frequency to 400 mg every 2 weeks. In addition, patients who lost clinical response after Week 10 switched to CIMZIA 400 mg every 2 weeks. The primary end point was mean change in CDEIS score from baseline to Week 10.

CD: Crohn’s disease; CDEIS: Crohn’s Disease Endoscopic Index of Severity; SD: standard deviation.

See CIMZIA Overview Identify CIMZIA Patients
CIMplicity Logo

CIMplicity can help provide ongoing support for your patients throughout their journey.

PATIENT SUPPORT

Interested in CIMZIA

In-Office Injection?

VISIT WEBSITE

Request Your Sample

Get a sample for your practice through our quick, easy sign-up form.

REQUEST A SAMPLE

IMPORTANT SAFETY INFORMATION & INDICATIONS

Serious and sometimes fatal side effects have been reported with CIMZIA, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (such as Legionella or Listeria). Patients should be closely monitored for the signs and symptoms of infection during and after treatment with CIMZIA. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member.

INDICATIONS

CIMZIA is a tumor necrosis factor (TNF) blocker indicated for:

  • Reducing signs and symptoms of Crohn’s disease (CD) and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy
  • Treatment of adults with moderately to severely active rheumatoid arthritis (RA)
  • Treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older
  • Treatment of adult patients with active psoriatic arthritis (PsA)
  • Treatment of adults with active ankylosing spondylitis (AS)
  • Treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation
  • Treatment of adults with moderate-to-severe plaque psoriasis (PSO) who are candidates for systemic therapy or phototherapy

IMPORTANT SAFETY INFORMATION (CONT’D)

CONTRAINDICATIONS

CIMZIA is contraindicated in patients with a history of hypersensitivity reaction to certolizumab pegol or to any of the excipients. Reactions have included angioedema, anaphylaxis, serum sickness, and urticaria.

SERIOUS INFECTIONS

Patients treated with CIMZIA are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Discontinue CIMZIA if a patient develops a serious infection or sepsis.

Reported infections include:

  • Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before CIMZIA use and during therapy. Initiate treatment for latent TB prior to CIMZIA use.
  • Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.
  • Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.

Carefully consider the risks and benefits of treatment with CIMZIA prior to initiating therapy in the following patients: with chronic or recurrent infection; who have been exposed to TB; with a history of opportunistic infection; who resided in or traveled in regions where mycoses are endemic; with underlying conditions that may predispose them to infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with CIMZIA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.

  • Do not start CIMZIA during an active infection, including localized infections.
  • Patients older than 65 years, patients with co-morbid conditions, and/or patients taking concomitant immunosuppressants may be at greater risk of infection.
  • If an infection develops, monitor carefully and initiate appropriate therapy.

MALIGNANCY

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member.

  • Consider the risks and benefits of CIMZIA treatment prior to initiating or continuing therapy in a patient with known malignancy.
  • In clinical trials, more cases of malignancies were observed among CIMZIA-treated patients compared to control patients.
  • In CIMZIA clinical trials, there was an approximately 2-fold higher rate of lymphoma than expected in the general U.S. population. Patients with rheumatoid arthritis, particularly those with highly active disease, are at a higher risk of lymphoma than the general population.
  • Malignancies, some fatal, have been reported among children, adolescents, and young adults being treated with TNF blockers. Approximately half of the cases were lymphoma, while the rest were other types of malignancies, including rare types associated with immunosuppression and malignancies not usually seen in this patient population.
  • Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers, including CIMZIA. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn’s disease or ulcerative colitis, and the majority were in adolescent and young adult males. Almost all of these patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. Carefully assess the risks and benefits of treating with CIMZIA in these patient types.
  • Cases of acute and chronic leukemia were reported with TNF blocker use.

HEART FAILURE

  • Worsening and new onset congestive heart failure (CHF) have been reported with TNF blockers. Exercise caution and monitor carefully.

HYPERSENSITIVITY

  • Angioedema, anaphylaxis, dyspnea, hypotension, rash, serum sickness, and urticaria have been reported following CIMZIA administration. If a serious allergic reaction occurs, stop CIMZIA and institute appropriate therapy. The needle shield inside the removable cap of the CIMZIA prefilled syringe contains a derivative of natural rubber latex that may cause an allergic reaction in individuals sensitive to latex.

HEPATITIS B VIRUS REACTIVATION

  • Use of TNF blockers, including CIMZIA, may increase the risk of reactivation of hepatitis B virus (HBV) in patients who are chronic carriers. Some cases have been fatal.
  • Test patients for HBV infection before initiating treatment with CIMZIA.
  • Exercise caution in patients who are carriers of HBV and monitor them before and during CIMZIA treatment.
  • Discontinue CIMZIA and begin antiviral therapy in patients who develop HBV reactivation. Exercise caution when resuming CIMZIA after HBV treatment.

NEUROLOGIC REACTIONS

  • TNF blockers, including CIMZIA, have been associated with rare cases of new onset or exacerbation of central nervous system and peripheral demyelinating diseases, including multiple sclerosis, seizure disorder, optic neuritis, peripheral neuropathy, and Guillain-Barré syndrome.

HEMATOLOGIC REACTIONS

  • Rare reports of pancytopenia, including aplastic anemia, have been reported with TNF blockers. Medically significant cytopenia has been infrequently reported with CIMZIA.
  • Consider stopping CIMZIA if significant hematologic abnormalities occur.

DRUG INTERACTIONS

  • Do not use CIMZIA in combination with other biological DMARDs.

AUTOIMMUNITY

  • Treatment with CIMZIA may result in the formation of autoantibodies and, rarely, in development of a lupus-like syndrome. Discontinue treatment if symptoms of a lupus-like syndrome develop.

IMMUNIZATIONS

  • Avoid use of live vaccines during or immediately prior to initiating CIMZIA. Update immunizations in agreement with current immunization guidelines prior to initiating CIMZIA therapy.

ADVERSE REACTIONS

  • The most common adverse reactions in CIMZIA clinical trials (≥8%) were upper respiratory infections (18%), rash (9%), and urinary tract infections (8%).

 

Please refer to full Prescribing Information.

US-CZ-2400612